Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 12.65 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 13.86 | Oscillator | Buy |
| Williams %R (14) | -87.61 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.25 (Hist 0.02) | Oscillator | Buy |
| Average Directional Index (14) | 69.37 (+DI 4.2 / -DI 36.8) | Trend | Strong Sell |
Current price $0.3863
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 17, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 24, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 20, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 31, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Dec 10, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
| Nov 15, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
| Nov 1, 24 |
| EMA 20 | 0.63 | MA | Strong Sell |
| SMA 20 | 0.63 | MA | Strong Sell |
| EMA 50 | 1.52 | MA | Strong Sell |
| SMA 50 | 1.05 | MA | Strong Sell |
| SMA 200 | 9.47 | MA | Strong Sell |
| HC Wainwright & Co. |
| maintain |
| Buy |
| Buy |
| Aug 1, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 15, 24 | Truist Securities | maintain | Buy | Buy |
TTM vs. 5-year historical average (annual ratios)
| Metric | CRIS | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.0x | -2.8x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.0x | EPS est. -47.14 | Discount |
| Price / Book | 0.2x | 1.7x | Discount |
| Price / Sales | 0.2x | 11.2x | Discount |
| EV / EBITDA | 0.2x | -2.7x | Discount |
| Return on equity | -1035.3% | — | Weak |
| Gross margin | 99.3% | 97.8% | In line |
| Debt / Equity | 0.22 | 0.02 | Conservative |
| Piotroski / Altman Z | 0/9 | Z -98.47 | Distress |
Discounted cash flow model
FY2025 · 10-K disclosure
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jul 7, 26 | Rubin Marc | director | A-Award | 6,800 @ $5.29 | $35.97K |
| Jul 7, 26 | Kaitin Kenneth I | director | A-Award | 6,800 @ $5.29 | $35.97K |
| Jul 7, 26 | Hohneker John | director | A-Award | 6,800 @ $5.29 | $35.97K |
| Jul 7, 26 | Greenacre Martyn D | director | A-Award | 6,800 @ $5.29 | $35.97K |
| Jul 7, 26 | Borgman Anne Elizabeth | director | A-Award | 6,800 @ $5.29 | $35.97K |
| Jul 7, 26 | Duvall Diantha | officer: CFO | A-Award | 48,285 @ $5.29 | $255.4K |
| Jul 7, 26 | Zung Jonathan B. | officer: CDO | A-Award | 48,285 @ $5.29 | $255.4K |
| Jul 7, 26 | Dentzer James E | director, officer: President & CEO | A-Award | 110,090 @ $5.29 | $582.4K |
Stock news · updated daily
LEXINGTON, Mass., Oct. 16, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS) ("Curis" or the "Company"), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it has entered into securities purchase agreements with certain existing healthcare focused institutional investors for the purchase and sale of 16,666,680 shares of common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and common warrants to purchase up to 16,666,680 shares of common stock at an effective combined price of $0.51 per share (or pre-funded warrant) and accompanying common warrant (the "Offering").
LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of common stock at a combined public offering price of $1.50 per share and accompanying common warrant (or a combined public offering price of $1.49 per pre-funded warrant and accompanying common warrant) (the "Offering").
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 14, 2026 | -6.95 | -4.02 | Beat 42.2% | — |
| May 12, 2026 | -5.80 | -25.00 | Miss -331.0% | — |
| Mar 19, 2026 | -8.72 | 24.60 | Beat 382.1% | $1.14M |
| Nov 6, 2025 | -12.40 | -9.80 | Beat 21.0% | $3.18M |
| Aug 5, 2025 | -39.80 | -13.60 | Beat 65.8% | $2.75M |
| May 6, 2025 | -22.80 | -25.00 | Miss -9.6% | $2.38M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| PRE 14A | Oct 23, 2026 | 2026-10-23 07:00:23 | View |
| 8-K | Oct 19, 2026 | 2026-10-19 16:30:24 | View |
| 424B4 | Aug 13, 2026 | 2026-08-13 17:27:13 | View |
| EFFECT | Aug 12, 2026 | 2026-08-13 00:15:08 | View |
| S-1 | Aug 10, 2026 | 2026-08-10 17:30:02 | View |
| 8-K | Jul 30, 2026 | 2026-07-30 16:01:43 | View |
| 4 | Jul 9, 2026 | 2026-07-09 16:12:43 | View |
| 4 | Jul 9, 2026 | 2026-07-09 16:12:26 | View |
| 4 | Jul 9, 2026 | 2026-07-09 16:12:01 | View |
| 4 | Jul 9, 2026 | 2026-07-09 16:11:39 | View |
Proxy statement (DEF 14A) disclosures